◆英語タイトル:Zavante Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014126
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Zavante Therapeutics Inc (Zavante), formerly SG Pharmaceuticals Inc is a developer of novel therapies for the treatment of infectious diseases. The company offers drugs for the treatment of diseases that affect patients in the hospital setting. Its lead product candidate ZOLYD, is an investigational first-in-class injectable epoxide antibiotic. Zavante’s ZOLYD is being developed for the treatment of infectious diseases such as complicated urinary tract infections, acute bacterial skin and skin structure infections, and others. The company works in collaboration with private and public firms to conduct its research and development activities. Zavante is headquartered in San Diego, California, the US.
Zavante Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Zavante Therapeutics Raises USD35 Million in Series A Financing 10
Zavante Therapeutics Raises Additional USD10.3 Million in Venture Financing 12
Zavante Therapeutics Secures USD4.18 Million Financing Round 13
SG Pharma Raises Funds through Venture Financing 14
Partnerships 15
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 15
Zavante Therapeutics Inc – Key Competitors 16
Zavante Therapeutics Inc – Key Employees 17
Zavante Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Sep 06, 2016: Healthcare Veteran Stephen L. Newman, M.D., Joins Zavante Therapeutics’ Board Of Directors 19
Product News 20
04/05/2017: Zavante Therapeutics’ ZOLYD Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections 20
Clinical Trials 22
Jan 19, 2017: Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 22
Jul 12, 2016: Zavante Lead Product Candidate, ZTI-01 (fosfomycin for injection) Demonstrated In Vitro Activity Against Bacteria Resistant To Last Resort Antibiotic 23
Jul 11, 2016: Zavante Enrolls First Patient In The ZEUS Study For ZTI-01 For The Treatment Of Complicated Urinary Tract Infections 24
Apr 14, 2016: Zavante Initiates The ZEUS Study For ZTI-01 For Urinary Tract Infections 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Zavante Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Zavante Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Zavante Therapeutics Raises USD35 Million in Series A Financing 10
Zavante Therapeutics Raises Additional USD10.3 Million in Venture Financing 12
Zavante Therapeutics Secures USD4.18 Million Financing Round 13
SG Pharma Raises Funds through Venture Financing 14
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 15
Zavante Therapeutics Inc, Key Competitors 16
Zavante Therapeutics Inc, Key Employees 17
Zavante Therapeutics Inc, Other Locations 18